1. Home
  2. SHIP vs DMAC Comparison

SHIP vs DMAC Comparison

Compare SHIP & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seanergy Maritime Holdings Corp.

SHIP

Seanergy Maritime Holdings Corp.

HOLD

Current Price

$14.09

Market Cap

335.9M

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.30

Market Cap

342.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHIP
DMAC
Founded
2008
2000
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.9M
342.7M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
SHIP
DMAC
Price
$14.09
$6.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$17.00
$15.50
AVG Volume (30 Days)
213.1K
157.7K
Earning Date
05-26-2026
05-13-2026
Dividend Yield
2.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
$20.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.11
$3.48
52 Week High
$16.86
$10.42

Technical Indicators

Market Signals
Indicator
SHIP
DMAC
Relative Strength Index (RSI) 39.62 64.22
Support Level $13.62 $6.56
Resistance Level $15.06 $7.27
Average True Range (ATR) 0.74 0.40
MACD -0.18 0.12
Stochastic Oscillator 5.96 88.70

Price Performance

Historical Comparison
SHIP
DMAC

About SHIP Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through a modern fleet of Capesize vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: